NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130970&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Trade Desk, Inc. ("The Trade Desk") (NASDAQ:TTD) concerning possible violations of federal securities laws. The Trade Desk reported Q4 revenue of $741 million, falling well below the company's prior guidance from its November 7, 2024, earnings call, where The Trade Desk projected "at least" $756 million in revenue.Following these results, shares of The Trade Desk Inc. fell over 30%.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Olin Corporation ("Olin Corporation") (NYSE:OLN) concerning possible violations of federal securities laws. Olin issued a press on January 30, 2025, reporting its financial results for the fourth quarter of 2024.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your FMC Corporation (NYSE:FMC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fmc-corporation-lawsuit-submission-form?prid=130975&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=130951&wire=1 or contact Joseph E.

Cloud communications specialist Bandwidth (BAND -6.57%) reported mixed fourth-quarter financial results on Thursday, Feb. 20. A key highlight was generating record revenue of $210 million, up 27% year over year and exceeding analyst consensus estimates of $203 million.

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

After snapping its 20-day win streak earlier this week, is Meta Platforms (META) stock overdue for a split? Citi senior analyst of Internet Equity Research Ron Josey says that a split is unlikely, going on to underline Meta's user growth across its platforms — Facebook, Instagram, Threads — and growth in AI spending and advertising revenue.

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

ETSY's Q4 2024 earnings beat estimates. However, revenues miss due to lower gross merchandise sales.

When investors think about monster stocks that went stratospheric over the past decade, companies like Nvidia (NASDAQ:NVDA) quickly come to mind.

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.

Cheniere Energy (LNG -0.50%), a global player in liquefied natural gas (LNG) production and export, announced its Q4 2024 financial results on Feb. 20, 2025. Earnings exceeded analysts' expectations for earnings per share (EPS) but showed a decline in revenue and net income from the previous year.

Orion S.A. (NYSE:OEC ) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Company Participants Chris Kapsch - Vice President-Investor Relations Corning Painter - Chief Executive Officer Jeff Glajch - Chief Financial Officer Conference Call Participants Josh Spector - UBS Laurence Alexander - Jefferies John Roberts - Mizuho Securities Jon Tanwanteng - CGS Securities Operator Greetings, and welcome to the Orion Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

NEW YORK , Feb. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zeta Global Holdings Corp. (NYSE: ZETA) on behalf of the company's shareholders. The investigation seeks to determine whether Zeta's directors breached their fiduciary duties in connection with recent corporate actions.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Feb. 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" …

HOUSTON , Feb. 20, 2025 /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today announced that its Board of Directors has approved an increase in its quarterly cash dividend to thirty two cents per share of common stock. This quarterly cash dividend declared today represents a 6.7% increase from the previously declared quarterly dividend of thirty cents per share of common stock per quarter.

Pre-markets are once again starting off lower, but the S&P 500 is working on a two-day record-closing-high.

DVN reports better-than-expected fourth-quarter earnings and revenues. The company continues to enjoy benefits from its multi-basin assets.